Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

Authors

S S. Ramalingam
J Mazieres
D Planchard
T E. Stinchcombe
G K. Dy
S J. Antonia
L Horn
H Lena
E Minenza
B Mennecier
G A. Otterson
L T. Campos
D R. Gandara
B P. Levy
Suresh G. Nair MD, Lehigh Valley Health NetworkFollow
G Zalcman
J Wolf
C Baudelet
B J. Lestini
N A. Rizvi

Publication/Presentation Date

12-2014

Volume

90

Issue

5

First Page

1266

Last Page

1267

Published In/Presented At

https://doi.org/10.1016/j.ijrobp.2014.09.038

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division

Document Type

Article